New York, NY, United States of America

Lloyd J Old

USPTO Granted Patents = 122 

 

 

Average Co-Inventor Count = 5.1

ph-index = 19

Forward Citations = 1,417(Granted Patents)


Inventors with similar research interests:


Company Filing History:

goldMedal56 out of 525 
 
Ludwig Institute for Cancer Research Limited
 patents
silverMedal32 out of 512 
 
Sloan-kettering Institute for Cancer Research
 patents
bronzeMedal23 out of 559 
 
Memorial Sloan Kettering Cancer Center
 patents
48 out of 1,521 
 
Cornell Research Foundation Inc.
 patents
54 out of 11 
 
Sloan-kettering Institute
 patents
62 out of 2 
 
The New York Hospital-cornell Medical Center
 patents
72 out of 193 
 
New York Blood Center, Inc.
 patents
82 out of 1,332 
 
Commonwealth Scientific and Industrial Research Organisation
 patents
92 out of 8,369 
 
Massachusetts Institute of Technology
 patents
102 out of 3 
 
Institute of Molecular Biology and Genetics National Academy of Science of Ukraine
 patents
111 out of 4,177 
 
Abbott Laboratories Corporation
 patents
121 out of 3 
 
Scotgen Biopharmaceuticals Incorporated
 patents
131 out of 3 
 
Ludwig Institute of Cancer Research
 patents
141 out of 306 
 
Boehringer Ingelheim Gmbh
 patents
151 out of 2 
 
Sloan-kettering Cancer Center
 patents
161 out of 1 
 
Institute for Molecular Biology and Genetics National Academy of Science of Ukraine
 patent
171 out of 1,535 
 
Boehringer Ingelheim International Gmbh
 patents
181 out of 446 
 
Oxford University Innovation Limited
 patents
191 out of 1,325 
 
Yale University
 patents
201 out of 1,579 
 
Washington University
 patents
2115 out of 832,680 
Other
 patents
where one patent can have more than one assignee

Years Active: 1985-2019

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Antibodies
Cancer Therapy
Egf Receptor
Immune Response
Ny-Eso-1 Protein
Nucleic Acid Molecules
Colon Cancer
Breast Cancer Antigens
Small Cell Lung Cancer
Human Sarcoma Antigens
Mhc Class I
Mhc Class Ii
122 patents (USPTO):Explore Patents

Title: Lloyd J Old: Pioneering Cancer Therapies through Innovative Patents

Introduction:

Lloyd J Old, a renowned researcher and inventor based in New York, NY, has made significant contributions to the field of cancer therapy through his groundbreaking innovations and patented inventions. With an impressive record of 121 patents to his name, Old has been at the forefront of developing novel treatments targeting specific membrane transporters and epitopes that hold promise in cancer therapy. This article delves into Old's latest patents, highlights from his career, notable collaborations, and his impactful contributions to the field of cancer research.

Latest Patents:

Old's latest patents revolve around the membrane transporter NaPi2b (SLC34A2) as a target for therapy, particularly in the realm of cancer immunotherapy. His inventions include the identification of an ovarian cancer epitope using the monoclonal antibody MX35 and the subsequent development of antibodies, both humanized and chimeric, specifically directed against NaPi2b (SLC34A2) and the SLC34A2 peptide(s). These antibodies possess anti-tumor and anti-cancer activity and have demonstrated potential in stimulating an immunological response against cancer cells. Old's patents also encompass methods for generating immune responses, treatment of tumors, and cancer screening assays.

Career Highlights:

Throughout his illustrious career, Old has held significant positions at esteemed institutions dedicated to cancer research. He notably worked at the Ludwig Institute for Cancer Research Limited, where he played a pivotal role in advancing innovative approaches for cancer treatment. Additionally, Old's contributions at the Sloan-Kettering Institute for Cancer Research have been instrumental in furthering our understanding of cancer biology and developing promising therapies.

Collaborations:

Old's accomplishments would not have been possible without his collaborations with esteemed colleagues in the field. Notably, he has worked closely with Yao-tseng Chen, a fellow researcher known for his contributions to cancer therapeutics. Their collaboration has resulted in the development of state-of-the-art antibody-based therapies with great potential in cancer treatment. Another notable collaborator is Elisabeth Stockert, a respected figure in the field, whose expertise and insights have enriched Old's research endeavors.

Conclusion:

Lloyd J Old's extensive portfolio of patents, coupled with his remarkable career in cancer research, solidify his position as a trailblazer in the field of cancer therapy. His innovative approach, targeting membrane transporters and epitopes, showcases the potential of immunotherapy for cancer treatment. Through collaborations with esteemed researchers and institutions, Old has fostered advancements that hold great promise for patients battling cancer. His contributions continue to shape the landscape of innovative treatments, offering hope to individuals affected by this devastating disease.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…